Alpha Tau Medical Continues Its Winning Streak with First-Ever Brain-Cancer Patient Treated Outside the U.S.

WSW, NY, June 24th, 2026, FinanceWire

Alpha Tau Medical (NASDAQ: DRTS) announced yesterday that the first glioblastoma patient ever treated with Alpha DaRT outside the United States has undergone the procedure at Hadassah University Medical Center. The case is the latest in an unusually dense run of milestones for the small-cap oncology developer, arriving roughly three weeks after a major U.S. commercial partnership was signed and less than two weeks after the U.S. FDA cleared the Company’s pivotal brain-cancer trial to full enrollment.

In a single, minimally-invasive burr-hole procedure carried out under real-time stereotactic neuro-navigation, a multidisciplinary team led by Prof. Yigal Shoshan, Professor of Neurosurgery at Hadassah, delivered radium-224 sources directly into the recurrent tumor of a 77-year-old male patient with glioblastoma that had progressed despite prior surgery and radiation. Alpha Tau reports the procedure was completed safely and without unexpected complications. The patient was treated under the ALL broad-access protocol, a study designed to receive solid tumor patients in any location of the body that the Alpha DaRT delivery system can reach.

Glioblastoma is the most aggressive primary brain cancer in adults, with approximately 160,000 new cases diagnosed globally each year. Virtually every patient recurs after first-line therapy, typically within six to nine months. Median overall survival from the time of recurrence is only another six to nine months, with no established standard of care and most patients ineligible for repeat surgical resection. It is precisely that population that the procedure was designed to reach.

A Cadence of Catalysts That Has Not Let Up

The first-outside-the-U.S. brain-cancer treatment lands at the end of a quarter in which the catalyst calendar has not slowed.

On June 11, the U.S. FDA cleared Alpha Tau to complete enrollment in its multicenter REGAIN trial in recurrent glioblastoma, and authorized the addition of two new U.S. academic clinical sites. The clearance followed an interim safety review of the first three patients treated at The Ohio State University, who showed 100% local disease control and a 67% complete response rate per RANO criteria, with a single treatment-related serious adverse event that resolved.

Eight days earlier, on June 3, Alpha Tau announced a strategic collaboration with Tolmar to commercialize Alpha DaRT for U.S. urological cancers, starting with prostate. The deal included a $20 million Tolmar equity investment at $11.99 per share, a 25% premium to the 30-day volume-weighted average price, plus a $15 million manufacturing commitment and up to $161.5 million in clinical, regulatory, and commercial milestones for the first indication. Alpha Tau retains manufacturing and sells the finished therapy to Tolmar at 60% of net sales. The stock moved more than 20% on the news.

Earlier in the quarter, Alpha Tau announced strong overall survival results from its Alpha DaRT pancreatic cancer studies at the 2026 ASCO Annual Meeting on June 1, completed enrollment in its U.S. pivotal ReSTART skin-cancer trial of 88 patients on May 8, and reported the interim REGAIN brain-cancer data on May 11. Step back further, and the run extends to first-quarter Japanese marketing approval for Alpha DaRT in head and neck cancer in February, the Company’s first international approval, and first European pancreatic-cancer patients treated at sites in France in April and Italy in May.

Yesterday’s announcement is another distinct first: the first international clinical application of the Company’s proprietary brain delivery system, separate from any of the prior catalysts in pipeline, geography, or indication.

A Differentiated Lane in a Sector Still Drawing Capital

Targeted radiation continues to attract substantial outside investment. On April 13, 2026, Regeneron Pharmaceuticals and Telix Pharmaceuticals announced a collaboration to co-develop next-generation radiopharmaceutical therapies, with $40 million upfront for four initial programs and up to $2.1 billion in milestone payments across the structure. Most of that capital has flowed into systemic radioligand architectures, where a targeting antibody or peptide carries a radioactive isotope through the bloodstream. Alpha DaRT operates in a different lane: the radiation is delivered intratumorally, the targeting is physical rather than biological, and the therapy is administered in a single localized procedure.

That distinction has so far sat outside the radiopharma deal sheet, even as Alpha Tau has built a clinical footprint spanning three countries, five active U.S. trials, an approved indication in Japan, a U.S. commercial partner in Tolmar, and roughly $80 million in cash as of March 31.

The Setup From Here

The near-term catalyst path is already visible. The ReSTART pivotal skin-cancer trial moves toward data maturation and the planned U.S. PMA submission, the REGAIN brain-cancer trial advances toward full enrollment, the IMPACT pancreatic-cancer program continues to expand, and the Tolmar prostate-cancer collaboration moves toward its U.S. trial. Each is its own clock.

Clinical development in oncology carries real risk. Pivotal endpoints can disappoint, regulatory timelines can lengthen, and early signals are not approvals. But at a roughly $900 million market capitalization, with a string of 2026 catalysts already executed and another one delivered yesterday, Alpha Tau looks less like a single-trial story and more like a platform that the broader radiopharma trade has not yet had to take a position on.

Recent News Highlights from Alpha Tau Medical (DRTS)

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT at Hadassah University Medical Center in Israel

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation on behalf of Alpha Tau Medical Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact